Last Updated: November 16, 2026

Drug Sales Trends for ESTRACE VAG

« Back to Dashboard


Drug Sales Revenue Trends for ESTRACE VAG
Drug Units Sold Trends for ESTRACE VAG

Annual Sales Revenues and Units Sold for ESTRACE VAG

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
ESTRACE VAG ⤷  Start Trial ⤷  Start Trial 2022
ESTRACE VAG ⤷  Start Trial ⤷  Start Trial 2021
ESTRACE VAG ⤷  Start Trial ⤷  Start Trial 2020
ESTRACE VAG ⤷  Start Trial ⤷  Start Trial 2019
ESTRACE VAG ⤷  Start Trial ⤷  Start Trial 2018
ESTRACE VAG ⤷  Start Trial ⤷  Start Trial 2017
ESTRACE VAG ⤷  Start Trial ⤷  Start Trial 2016
>Drug Name >Revenues (USD) >Units >Year

Estrace Vaginal Cream Market Analysis and Sales Projections

Last updated: September 11, 2026

Estrace Vaginal Cream is a mature estradiol product competing with generic estradiol vaginal cream, vaginal tablets, inserts, rings, and systemic hormone therapy. Its commercial opportunity is stable but constrained by generic substitution, low-cost alternatives, limited differentiation, and prescriber movement toward lower-dose local estrogen products. Public filings do not disclose standalone Estrace Vaginal Cream revenue, so the projections below use an explicit unit-and-price model rather than reported manufacturer sales.

What is Estrace Vaginal Cream and how is it used?

Estrace Vaginal Cream contains estradiol 0.01% and is approved for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy caused by menopause. The product is administered intravaginally using a calibrated applicator. Its primary commercial indications are vaginal dryness, irritation, dyspareunia, and related genitourinary symptoms of menopause.[1]

Product attribute Estrace Vaginal Cream
Active ingredient Estradiol
Strength 0.01%, equivalent to 0.1 mg/g
Dosage form Vaginal cream
U.S. regulatory status FDA-approved prescription drug
Reference product Estrace
Main therapeutic category Genitourinary syndrome of menopause
Primary competitors Generic estradiol cream, Vagifem, Imvexxy, Estring, Osphena
Typical treatment Daily loading phase followed by maintenance dosing
Key commercial issue Generic substitution and payer preference

Estrace Vaginal Cream differs from systemic estrogen products because it is intended primarily for local vaginal symptoms. The approved label carries class warnings applicable to estrogen therapy, including risks associated with endometrial stimulation, cardiovascular events, breast cancer, and dementia.[1]

What is the FDA regulatory and Orange Book status of Estrace Vaginal Cream?

Estrace Vaginal Cream is an FDA-approved reference product. Generic estradiol vaginal cream products are available in the United States and have substantially reduced the reference product's pricing power.

The product's key regulatory characteristics are:

Regulatory factor Market impact
NDA reference product Establishes the clinical and pharmaceutical reference standard
Abbreviated New Drug Application pathway Allows generic manufacturers to rely on the reference product's safety and efficacy findings
Local vaginal administration Creates formulation and device considerations, but not a strong barrier to generic competition
Multiple approved generic products Increases pharmacy-level substitution
No biologic classification Biosimilar regulation does not apply
No meaningful biologic manufacturing barrier Production is based on a chemically synthesized active ingredient

The Orange Book is the relevant source for current patents, exclusivity, therapeutic-equivalence codes, and approved generic products.[2] Estrace Vaginal Cream is not a biologic and does not benefit from the 12-year reference-product exclusivity framework applicable to biologics under the Public Health Service Act.

When does Estrace Vaginal Cream lose exclusivity?

The principal exclusivity risk has already occurred. Estradiol is an old active pharmaceutical ingredient, and generic estradiol vaginal creams have entered the U.S. market. Commercial protection therefore depends more on brand loyalty, payer placement, distribution, and prescription retention than on core composition-of-matter rights.

Exclusivity category Estrace Vaginal Cream assessment
Composition-of-matter exclusivity Expired or commercially irrelevant because estradiol is an established molecule
New chemical entity exclusivity Not applicable to the current commercial lifecycle
Pediatric exclusivity No material current commercial effect identified
Orphan-drug exclusivity Not applicable
Reference-product exclusivity Exhausted for practical market purposes
Formulation protection Limited value against approved generic vaginal creams
Method-of-use protection Possible only for narrowly claimed uses and generally difficult to enforce against routine prescribing
Generic substitution exposure High

A current patent-expiration date should be taken from the live FDA Orange Book entry and applicable patent records. Public commercial information does not support treating an unexpired legacy patent as a significant barrier to generic access.

How large is the market for vaginal estrogen products?

The addressable market is driven by postmenopausal women with genitourinary syndrome of menopause who seek treatment for vaginal dryness, irritation, painful intercourse, urinary symptoms, or recurrent urinary discomfort. The market includes prescription estrogen products and nonprescription moisturizers and lubricants.

The U.S. prescription market is divided among several product types:

Segment Representative products Commercial position
Vaginal cream Estrace, generic estradiol cream, Premarin cream Broad use, flexible dosing, lower cost in generic form
Vaginal tablet Vagifem, generic estradiol vaginal inserts Lower mess and fixed-dose administration
Vaginal insert Imvexxy Premium pricing and convenience positioning
Vaginal ring Estring Long dosing interval and office or patient insertion
Oral non-estrogen therapy Osphena Alternative mechanism, systemic exposure
Nonprescription products Moisturizers and lubricants Low-cost substitutes, weaker pharmacologic effect

Estrace Vaginal Cream benefits from long clinical familiarity and broad prescriber awareness. Its disadvantages are application inconvenience, variable patient acceptance, and the availability of low-cost generic cream.

What are the main competitors to Estrace Vaginal Cream?

Generic estradiol vaginal cream

Generic estradiol cream is the direct competitor. It has the same active ingredient and broadly comparable route of administration. Pharmacy substitution and formulary requirements place the branded product under persistent price pressure.

Premarin Vaginal Cream

Premarin contains conjugated estrogens and has a distinct ingredient profile. It remains a major branded competitor, although its pricing and payer coverage can differ materially from estradiol products.

Vagifem and generic estradiol vaginal inserts

Vaginal tablets and inserts provide fixed dosing and reduced handling relative to cream. They can command higher net prices when patients or clinicians value convenience.

Imvexxy

Imvexxy is a low-dose estradiol vaginal insert positioned around comfort and ease of use. It competes for patients who prefer an insert over an applicator-delivered cream.

Estring

Estring delivers estradiol through a vaginal ring over an extended period. It has a convenience advantage but generally requires a higher upfront product cost and different insertion preferences.

How strong is the patent estate for Estrace Vaginal Cream?

The core patent estate is weak from a market-exclusion perspective. Estradiol is an old molecule, and the product's commercial value is not protected by a new chemical entity patent. Potential protection areas include:

  1. Cream composition and excipient combinations.
  2. Dose delivery through the applicator.
  3. Packaging and administration systems.
  4. Specific treatment schedules.
  5. Narrow methods of reducing or treating menopausal symptoms.

These rights generally have lower blocking power than composition-of-matter patents. Generic applicants can challenge patents through Paragraph IV certifications, design around formulation claims, or rely on patents that do not materially restrict approval.

Patent area Estimated defensive value
Estradiol molecule None for current commercial protection
Basic vaginal cream formulation Low to moderate
Applicator design Low unless tied to a necessary delivery feature
Dosing regimen Low to moderate, depending on claim scope
Specific patient population Limited and vulnerable to noninfringing labeling
Manufacturing process Low unless the process is necessary for product quality
Packaging Low

Are Paragraph IV challenges and patent litigation material risks?

The principal risk is continued generic substitution rather than a new wave of Paragraph IV litigation. Once multiple generic products are approved, a later challenge to a narrow patent usually has limited ability to restore branded market exclusivity.

Relevant litigation considerations include:

  • A Paragraph IV certification can accelerate patent litigation before generic launch.
  • A generic applicant may use a Section VIII statement to omit a patented method of use from its label.
  • Skinny-label strategies can reduce infringement exposure where the patented use is not necessary for the generic product.
  • Formulation patents are more vulnerable when the generic product has the same active ingredient and route but uses a different excipient system.
  • A settlement agreement could delay entry, but the value of delayed entry is reduced when other generic suppliers already exist.

No publicly established litigation event appears capable of restoring broad exclusivity for Estrace Vaginal Cream. Any current case-specific conclusion would require review of live federal court dockets and the current Orange Book entry.

What are the sales and revenue projections for Estrace Vaginal Cream?

A standalone forecast requires assumptions because the manufacturer does not publicly report Estrace Vaginal Cream revenue as a separate line item. The following model estimates U.S. brand and generic-equivalent vaginal cream revenue using prescription volume, net price, and annual erosion.

Base-case projection

Year Estimated U.S. equivalent units Blended net revenue per unit Estimated market revenue
2025 4.5 million $45 $203 million
2026 4.6 million $42 $193 million
2027 4.7 million $39 $183 million
2028 4.8 million $36 $173 million
2029 4.9 million $34 $167 million

The base case assumes prescription volume grows modestly as diagnosis and treatment of genitourinary syndrome of menopause increase, while average net revenue declines because of generic substitution and payer pressure. Under these assumptions, market revenue falls at approximately 4% annually despite unit growth.

Scenario analysis

Scenario 2025 market revenue 2029 market revenue Principal assumption
Downside $150 million $105 million Faster generic penetration and lower reimbursement
Base case $203 million $167 million Modest unit growth and gradual price erosion
Upside $250 million $270 million Greater diagnosis, stable branded retention, and stronger category expansion

These figures represent modeled U.S. vaginal cream market revenue, not reported Estrace brand sales. Brand-only revenue would be materially lower because generic estradiol captures a substantial share of prescriptions.

What is the commercial outlook for the Estrace brand?

The branded product's outlook is defensive rather than expansionary. Its commercial value rests on:

  • Recognition among gynecologists, primary-care physicians, and menopause specialists.
  • Longstanding clinical familiarity.
  • Patient continuity and refill behavior.
  • Coverage in selected commercial formularies.
  • Potential preference for the branded cream among patients who tolerate it well.

The main disadvantages are generic substitution, price differentials, competing dosage forms, and the absence of a strong patent barrier. Brand revenue is likely to decline unless the owner preserves access through contracting, patient support, or a differentiated delivery system.

A reasonable brand-retention range is 10% to 25% of the U.S. vaginal cream segment over the forecast period. At the base-case market values above, that implies potential brand-equivalent revenue of approximately $20 million to $51 million in 2025 and $17 million to $42 million in 2029. This range is a commercial estimate, not a reported financial result.

What generic launch risks exist?

Generic entry risk is high because:

  1. The active ingredient is well established.
  2. The product is chemically synthesized rather than biologic.
  3. The route of administration is familiar to generic manufacturers.
  4. Pharmacy substitution is straightforward.
  5. The reference product has limited remaining exclusivity value.
  6. Competing estrogen products already educate prescribers and patients.

The main technical barrier is not active-ingredient synthesis. It is demonstrating pharmaceutical equivalence, product performance, microbiological quality, preservative performance, rheological properties, and reliable applicator delivery. These requirements can increase development costs but do not create a durable barrier comparable to complex biologic manufacturing.

How does Estrace compare with competing vaginal estrogen products?

Product Main advantage Main weakness Relative commercial risk
Estrace cream Familiarity and flexible dosing Messier administration and generic competition High
Generic estradiol cream Low price Limited brand differentiation High competition, strong volume position
Vagifem Fixed-dose tablet format Higher cost than generic cream Moderate
Imvexxy Convenient insert and premium positioning Higher price and reimbursement sensitivity Moderate to high
Estring Extended dosing interval Insertion and device preference issues Moderate
Premarin cream Established brand and distinct estrogen profile Price and payer pressure High

Cream remains commercially relevant because it is flexible and often lower cost. Inserts and rings can maintain pricing power through convenience, but those products face their own reimbursement and substitution pressures.

What licensing or M&A activity affects Estrace Vaginal Cream?

No major licensing transaction is required to maintain the product's commercial position because Estrace is a mature marketed product. Potential strategic activity would more likely involve:

  • Acquisition of a women's-health portfolio.
  • Licensing of a vaginal delivery device.
  • Combination products for genitourinary syndrome of menopause.
  • Digital adherence or menopause-care platforms.
  • Distribution agreements with specialty pharmacies.

A transaction would be more defensible if it included differentiated delivery technology, improved adherence, or a formulation with a clear clinical benefit. A standalone legacy cream without exclusivity would command a lower valuation multiple than a product with protected formulation or device intellectual property.

Key Takeaways

  • Estrace Vaginal Cream is a mature estradiol product with high generic exposure.
  • The core molecule and reference-product exclusivity do not provide meaningful current protection.
  • Generic estradiol cream is the primary competitive threat.
  • Vagifem, Imvexxy, Estring, and Premarin compete through convenience, formulation, dosing, or brand positioning.
  • The modeled U.S. vaginal cream market is approximately $203 million in 2025 under the base case.
  • Base-case market revenue declines to about $167 million by 2029 as price erosion exceeds unit growth.
  • Estimated brand-equivalent revenue is substantially lower, potentially $20 million to $51 million in 2025.
  • Manufacturing and formulation requirements create development work but not a durable market barrier.
  • The commercial strategy is likely to focus on retention, payer access, and differentiation rather than patent-based exclusivity.

FAQs About Estrace Vaginal Cream Sales and Market Risk

Is Estrace Vaginal Cream still commercially important?

Yes. It remains a recognized local estrogen product, but its commercial importance is concentrated in prescription retention and brand familiarity rather than exclusivity.

Is generic estradiol cream therapeutically equivalent to Estrace?

Approved generic products are generally required to meet FDA standards for pharmaceutical equivalence and bioequivalence or applicable product-specific requirements. The Orange Book therapeutic-equivalence designation is the controlling regulatory reference.[2]

Can a new vaginal estrogen product obtain FDA exclusivity?

A new product may obtain exclusivity if it qualifies under the applicable FDA pathway, but an established estradiol formulation generally cannot obtain new chemical entity exclusivity. Protection would more likely depend on a novel formulation, device, indication, or delivery technology.

Does Estrace Vaginal Cream face biosimilar competition?

No. Estradiol is a chemically synthesized small molecule, not a biologic. Competition proceeds through generic-drug pathways rather than biosimilar approval.

What would increase Estrace Vaginal Cream sales?

Growth would require increased diagnosis and treatment of genitourinary syndrome of menopause, stronger brand retention against generic substitution, improved payer access, or a differentiated formulation or delivery system that supports premium pricing.

References

  1. U.S. Food and Drug Administration. (2014). Estrace vaginal cream, 0.01%: Prescribing information.
  2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.